Login to Your Account

Bio ’blastoff’: Tel Aviv biotech files for $37.5M IPO

By Marie Powers
Staff Writer

Monday, February 10, 2014
Bioblast Pharma Ltd. extended the 2014 initial public offering (IPO) window, filing an F-1 with the SEC seeking to raise up to $37.5 million and a listing on the Nasdaq Capital Market. The Tel Aviv firm filed as an emerging growth company under the Jumpstart Our Business Startups Act of 2012.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription